Hyperfine Inc. reported a record quarterly revenue of approximately $5.3 million in Q4 2025, marking a significant 54% growth compared to the previous quarter.
The full-year revenue for 2025 is estimated to be around $13.5 million, showing a 5% increase from the previous year.
The company's cash and cash equivalents as of December 31, 2025, are expected to be approximately $35.1 million.
Quarterly Revenue Growth
Q4 2025 revenue grew by 127% compared to Q4 2024 and by 54% sequentially from Q3 2025.
Net Cash Burn
Q4 2025 net cash burn is projected at approximately $5.7 million, a 30% decrease from Q4 2024.
Yearly Revenue Increase
Full-year 2025 revenue is expected to rise by 5% compared to the prior year.
Cash and Cash Equivalents
The company anticipates having $35.1 million in cash and cash equivalents as of December 31, 2025.
- Hyperfine's strong quarterly performance reflects a robust growth trajectory with significant revenue and cash position improvements.
- The increase in revenue and the decline in net cash burn indicate positive financial health and operational efficiency for the company.
Hyperfine's financial results for Q4 and full-year 2025 demonstrate remarkable growth and sound financial management, positioning the company for continued success in the health technology sector.